

1 Mortality and predictors of Chronic Kidney Diseases (CKD) in
2 selected dialysis centers in Addis Ababa, Ethiopia

3 Beza Zewdu Desta¹, Behailu Tariku Derseh², Abel Fekadu Dadi^{3, 4}

4 ¹ Ethiopian Food, Medicine Administration and Health care Authority

5 ² Departments of Public Health, Asrat Woldeyes Health Sciences Campus, Debre Berhan
6 University, Ethiopia

7 ³ Menzies School of Health Research, Charles Darwin University, Darwin, Australia

8 ⁴ Departments of Epidemiology and Biostatistics, College of Medicine and Health
9 Sciences, University of Gondar, Gondar, Amhara, Ethiopia

10 Corresponding author: Beza Zewdu Desta: bezazewdu23@gmail.com

11

12 Email:

13 Behailu Tariku Derseh: minastariku@gmail.com

14 Abel Fekadu Dadi: fekten@yahoo.com

15 **Abstract**

16 **Background:** Chronic Kidney Disease (CKD) affects 10-15% of the population
17 worldwide. The number of dialysis patients is steadily rising in Ethiopia. Chronic
18 hemodialysis patients experience high rates of mortality; however, data is lacking in
19 Ethiopia. We explored the mortality and its driving factors in selected dialysis center in
20 Addis Ababa

21 **Method:** we retrospectively followed a group of End-Stage Renal Disease patients on
22 hemodialysis from 2016 to 2020 in St. Paul Millennium Medical College (SPMMC),
23 Zewditu Memorial Hospital (ZMH), and Menelik II Hospital. We fitted Kaplan Meier
24 analysis to estimate the one and five year's survival probability of these patients and
25 Cox Proportional regression analysis to model the predictors of mortality at p value
26 ≤ 0.05 .

27 **Result:** We analyzed a data of (139) patients under follow up. The mean age (\pm SD) of
28 the patients was 36.8 (± 11.95) years. Twenty-four (17%) of the patients died at the end
29 of follow-up. The median survival time was 46.2 months (95% CI: 41.8, 50.5). The one
30 and five-year's survival probability of these patients was 64.8% and 18.7%,
31 respectively. Our analysis showed that patients with hypertension (AHR = 4.33; 95% CI:
32 1.02, 34.56), cardiac complication (AHR = 4.69; 95% CI: 1.32, 16.8), and infection during
33 dialysis (AHR = 3.89; 95% CI: 1.96, 13.8) were more likely to die.

34 **Conclusion:** The survival status of hemodialysis patients in three was low. Preventing
35 and treating comorbidities and complication during dialysis would reduce mortality of
36 CKD patients.

37 **Keywords:** Kaplan Meier estimate, Incidence, Kidney failure, Survival analysis

38 Introduction

39 Chronic kidney disease (CKD) is a major public health problem that challenging health
40 system around the world(1). Chronic Kidney disease (CKD) is a progressive loss of
41 kidney function over a period of months or years. Professional guidelines classified the
42 severity of CKD in five stages. A clinically significant Stage 5 CKD or end-stage renal
43 disease is the most deliberating stage in which the patient should get Renal
44 Replacement Therapy(RRT) (2).

45 A death associated with CKD has nearly be doubled worldwide between 1990 and
46 2010 and was the 18 highest cause of death in 2010 (3). It is estimated that by 2030
47 more than 70% of patients with end-stage renal disease will be living in low-income
48 countries (4).

49 Renal replacement therapy (RRT) is the mainstay of care for patients with an end stage
50 renal disease(ESRD) to reduce mortality and morbidity (5).

51 Patients with end-stage renal diseases (ESRD) are unable to sustain life without dialysis
52 support(6). That would last about 3 to 4 hours a week. The duration of each session
53 depends on how well the patient's kidneys work, and how much fluids weight the
54 patient has gained between treatments (6).There are three main types of vascular
55 accesses (VA) used in HD treatment: Arterio-Venous Fistula (AVF), Synthetic Arterio
56 Venous Graft (AVG), and Central Venous Catheter (CVC) (7). All types of VA have their
57 own risks and expensive. The clinical practice guidelines recommend , AVF as first
58 choice because of its reduced associated complications, morbidity, and mortality
59 compared with the AVG and CVC(8).

60 Although there is limitation of data about prevalence of CKD, few studies indicate that
61 renal disease has become a significant public health problem in Ethiopia. A cross
62 sectional study showed that the prevalence of CKD in Ethiopia is estimated to be 12.2%
63 and increased in the last few years following an increasing prevalence of diabetes and
64 hypertension. The prevalence of CKD is as high as 41.0% in age <35 years and 62% in
65 males (9).

66 The high rate of mortality among dialysis patients after initiation of the therapy is
67 attributed to factors such as demographic, comorbidities, blood markers such as
68 albumin and hemoglobin, and type of vascular access (10)

69 Duration of dialysis per session, hypertension, and infection status significantly affect
70 the survival rate of ESRD. (11).

71 A study on survival pattern of hemodialysis patient in Ethiopia shows that 45.1 % of
72 death occurs during dialysis treatment and 23.1 % of the patient died within the first 90
73 days of initiation of dialysis, while only 42.1% of the patients survive more than a year.
74 Septicemia (34.1%) , cardiovascular disease (29.3%) and uses of the catheter as
75 vascular access was associated with a short and long term survival of patients treated
76 with hemodialysis (5).

77 There is limited data reporting mortality and its predictors among chronic hemodialysis
78 kidney patients that we intended to investigate in this study.

79 **Methodology**

80 **Study setting and period**

81 We analyzed a retrospectively recorded data of patients enrolled in a maintenance
82 hemodialysis in three hospitals in Addis Ababa (St. Paul Millennium Medical College
83 (SPMMC), Zewditu Memorial Hospital (ZMH), and Menelik II) from 1stJanuary 2016 to
84 30th December 2020.

85 Addis Ababa has a population size of 3,435,028 of whom 1,809,577 are females
86 (12).There are 13 publics and 34 privates hospitals in the centers providing different
87 public health services.

88 We included all chronic kidney patients age 18 years and above who were on
89 hemodialysis for End-Stage Renal Disease during the study period.

90 We excluded: (1) Patients who starts hemodialysis for acute renal failure or patients
91 who started dialysis on an emergency basis or acute dialysis (with the duration from
92 first to last dialysis being less than 30 days); (2) those with incomplete medical
93 record/charts for important variables; and (3) alive patients transferred into COVID- 19
94 center with their medical cards as these patients had restricted access.

95 **Outcome of interest**

96 The outcome is death of patients happening during the time of hemodialysis and we
97 both interested in modeling the mortality and time. Right censored patients were those
98 alive, default, and transferred during the time of follow up. The start of the follow-up
99 was the time the patient started maintenance hemodialysis. We calculated an incidence
100 rate by considering the time of follow-up of each patient contribute to the exposure
101 time.

102 **Covariates**

103 We did a literature review to identify the potential risk factors associated with death.
104 The covariates included: (1) Sociodemographic such as age , sex, marital status,
105 residence; (2) weight in kg, comorbidities such as hypertension, diabetes mellitus,
106 cancer, chronic kidney disease-mineral and bone disorder (CKD-MBD), types of vascular
107 access for dialysis (AV Fistula, Grift, Catheter); (3) cardiovascular disease such as
108 coronary artery disease (CAD), cardiac arrhythmia, cardiac failure, cardiac valvular
109 disease, pericardial disease, cardiomyopathy, and congenital heart disease; (4)
110 biochemical profile of the patients such as Serum levels of hemoglobin, creatinine,
111 albumin, Phosphorus; (5) duration of dialysis per season and frequency of dialysis per
112 week.

113 **Data source**

114 We extracted the required data from medical records and hemodialysis registration
115 books using a pretested data extraction form. The investigator further checked for the
116 validation and completeness of the extracted data. The variables included in this study
117 were recorded in an Excel file. Missing values for important variables were completed
118 by reviewing clinical notes and reports available in the selected dialysis center. Trained
119 two Masters of Public Health Students and two Bachelor of nursing from each hospital,
120 and one supervisor were involved in the data extraction and validation. Both supervisor
121 and data collectors were trained for two days on how to extract data, what to be
122 extracted and to make them internalize the context of each question in the data
123 extraction form.

124 **Data analysis**

125 We entered the extracted data into Epi data and exported to SPSS for further analysis.
126 We used mean or median and standard deviation to present numeric data and
127 frequencies and percentages to present a categorical data.

128 We computed the person-time of follow-up from the date of starting hemodialysis to
129 death, loss to follow-up, or the end of the study. We calculated the Incidence rate of
130 death by dividing the number of deaths among CKD patients occurring by person-
131 months of follow-up. We used actuarial life table to estimate survival after initiation of
132 hemodialysis; and the Kaplan-Meier test to estimate the probability of death and the
133 median time to death after initiation of hemodialysis. We did log-rank test to compare a
134 time to death between different covariates. We checked assumption of proportional
135 hazard model using the Log (-log (St)) plots and tests. We used the Cox proportional
136 hazard model to determine the probability of death after initiation of hemodialysis
137 adjusting for confounding factors. We excluded covariates that violate the assumption
138 of cox proportional hazard model from the analysis. All statistically significant variables
139 having a p-value ≤ 0.25 in the bivariate analysis were adjusted in the final model. We
140 estimated the crude and adjusted hazard ratio (HR) and its 95% confidence interval (CI)
141 were estimated to identify and report significant predictors of death at p-value < 0.05 .

142 **Results**

143 We found total of 139 chronic dialysis patients who started a dialysis between January
144 1, 2016, and December 30, 2020.

145 **Socio demographic characteristic of the patients**

146 Table 1 presents the characteristics of patients included in this study. Slightly above half
147 of the patients were males 88 (63.3%). The mean (\pm SD) age at dialysis initiation was
148 36.81(\pm 11.50) years and more than half were in younger age category (18-34 years)
149 (show table 1).

150 Majority of the patients 102(73.4%) were living in Addis Ababa while the rest 26.6 %
151 (37) came to Addis for treatment from different regions of Ethiopia(show table 1).

152 **Baseline characteristics of the patients**

153 The mean (\pm SD) of systolic blood pressure was 143.25 mmHg (\pm 22.063) at the initiation
154 of dialysis. The mean of blood pressure at the last session of dialysis was 142.10
155 (\pm 19.083 mmHg). The mean (\pm SD) weight of the patients at dialysis initiation of dialysis
156 was 55.54 kg (show table 2).

157 **Treatment modality**

158 Most of the patients (89.2%) had three sessions of dialysis per week. Duration of each
159 session ranged between three to four hours. Most of the patients 121(87.1%) had four
160 hours of stay in dialysis.

161 More than half (63.3%) of the hemodialysis patients were taking their treatment by
162 Arteriovenous Fistula (AVF) followed by catheter (AVC) 36%.

163 About more than 80% of the patients were given some form of medication for
164 complications of CKD and hemodialysis treatment and 82.2% of the patient were taking
165 Erythropoietin (EPO). Twenty -four (17.3 %) of the patients had been given a blood
166 transfusion at least once during their time on dialysis. The most common causes of
167 ESRD were hypertension (48.2%), diabetes mellitus (6.5%), Glomerulonephritis (6.5%),
168 Renal Stone (2.2 %) and 36.7% of the ESRD patients had unknown etiology (show table
169 4 and 5).

170 **Comorbidity and complication**

171 Some forms of comorbidities were occurred in 78(56.1%) of the patients.
172 Cardiovascular complication was the most common comorbid complication recorded in
173 53.2% of the patients as moderate-severe mitral regurgitation and diastolic
174 dysfunction. Seventy-eight (56.1%) of the patients were developed different types of
175 infections sometimes in their course of treatment. For example, Hypotension occurred
176 in (36.0%) of the patients at least once during the period of dialysis (show table 4).

177 **Survival status of patients on hemodialysis**

178 About 24 (17%) patients died and the rest 115(83%) were censored during the follow
179 up. The sample included 88 male patients of which 15(17%) were died and 51 females
180 of which nine were (17.65%) died. Twenty four patients were died during the first 60
181 months follow-up. Among these, 10 and 4 were dead during the first and second six

182 months of follow-up, respectively. The median survival time was 46.2 months and the
183 overall survival rate was 86% at one year and 70% at five years.

184 **Predictors of mortality**

185 Hypertension, cardiovascular complication, infection, and types of vascular access were
186 turned-out to predict the mortality in adjusted model (show figure 1 and table 7). As
187 such being hypertensive increased the risk of mortality by 4.3 times (95%CI: 1.02-
188 18.43).

189 Patients with cardiovascular complication had a 4.7 (95%CI: 1.32-16.76) times higher
190 risk of mortality. The risk of mortality among patients using Arterio-Venous Graft and
191 temporary venous catheter were 19.57 (95%CI: 2.01-190.74) and 3.84(95%CI: 1.40,
192 10.50) times higher than those patients using Arterio-Venous Fistula. Furthermore, a
193 risk of mortality was 3.59 (95%CI: 1.98-13.05) times higher among patients with
194 comorbid infection.

195 **Discussion**

196 Dialysis remains the priority intervention for patients with advanced CKD as there are
197 limited organs for transplantation and excesses risks associated with the
198 transplantation for most of patients worldwide. Dialysis prolong and improve quality of
199 life of patients with kidney failure, and this needs a continues evaluation of the
200 procedure to improve treatment outcomes. We aimed to conduct this secondary data
201 analysis as an evaluation and to inform clinicians about factors that trigger the
202 mortality of patients in dialysis centers in Addis Ababa.

203 The median follow-up time of the patients was 46.2 months and its consistent with
204 patients in Adama hospital that estimated to be 43 months(13). Furthermore, the
205 survival rate of patients under follow up was 70% at 5-years and 86% at 1-years which
206 relatively the same with a similar study reported elsewhere which reported to be
207 80%(14). Another study from Brazil reported a survival rate of 84.7% in the first and
208 63.3% in the five years of treatment (15). The main reason for the discrepancy might be
209 the low accessibility and cost of the service in Ethiopia. The lower long-term survival
210 rate of the patients could be attributed to in that undergoing dialysis is very low and
211 can be attributable to medical conditions that we have identified including; types of
212 vascular access type, hypertension, infection status, and cardiac complications.

213 Patients with cardiovascular complications had around four times increased risk of
214 mortality compared to those patients with no cardiac complications. In another way, the
215 mean survival months of patients with cardiac complication was 14 months lower. This
216 result is similar to a study reported from China; were cardiac complication was a
217 statistically significant predictor of mortality among ESRD patients(16). Similarly, we
218 found a cumulative hazard of mortality that was three times among patient with CVD
219 complications it has been reported that stroke was a prominent predictor of all-causes
220 of mortality in patients who had cardiovascular complications (16). The burden of
221 chronic kidney disease on mortality is significant and continues to increase, which
222 requires, optimal medical management. Studies reported the excess of cardiovascular
223 morbidity and mortality in patients with renal insufficiency particularly (17).

224 The risk of death for ESRD patients with infection was about three times higher than
225 that than of the patients on hemodialysis without infection. Similar study in Ethiopia
226 found a risk of death in patients in maintenances hemodialysis with septicemia which
227 accounts for 34.1% of all-cause of mortality (5). Another study from Taiwan found a
228 risk which is lower but in similar direction. Having infection and advanced CKD
229 increased the risk from all cause of mortality by 34% in the first year and 19% during
230 the nine years follow up period (18). Efforts at minimizing infectious complications,
231 preventing infection at any level should increase survival among hemodialysis patients.

232 In the present study, another factor that was identified as a predictor of mortality
233 among patients on hemodialysis was the type of vascular access for hemodialysis
234 treatment. Those who were on arteriovenous Catheter had a risk of mortality about four
235 times compared to those patients with AVF access. This result is consistent with a study
236 reported in Iran a 3.6-fold higher risk of death (19). This study showed that a vascular
237 access using catheter accompanied with increased risk of death and this is highly likely
238 as the fact that. In fact, limiting the use of catheters minimized the infection
239 complications in patients.

240 Another two studies show that catheter use was associated with a mortality risk of 67%
241 and three times as compared with use of an AVF(17). We similarly found a risk of
242 mortality of about 47% higher among patients who used Catheter.

243 Dissimilar to our result a retrospective cohort study in Belgium found a vascular access
244 type was not independently correlated with patient survival, even after taking into
245 account change of vascular access over time(20). And also the result of this study is

246 consistent with nighty one hemodialysis case summary of hemodialysis patents in
247 Ethiopia revel that patients who had catheter as permanent vascular access was
248 associated with poor outcome as compared to artery venous fistula and Graft and one-
249 year survival rate for AVC group were 5.4 % and 66.9 % in other types of vascular
250 access(p-value <0.0001)(5). In summary most of studies found that Arteriovenous
251 catheter increases the risk of death compared to other vascular access. This might be
252 due to a high risk of infection in patient taking treatment by AVC.

253 Hypertension were another significant predictor of mortality in risk of having that was
254 four times. High blood pressure in our analysis was associated with a mortality risk of
255 four times and this is inconsistent with studies that found reverse association i.e., high
256 blood pressure associated with low risk and low blood pressure associated with high
257 risk of mortality in dialysis patients. Contradict to this study some of the existing studies
258 refer to this phenomenon as “reverse epidemiology”, indicating a paradoxical
259 association between mortality and the effect of hypertension in dialysis patients. This
260 paradoxical phenomenon of lower BP or a decline in BP over time is associated with
261 increased mortality and higher BP is associated with lower mortality is described as
262 “reverse” epidemiology of hypertension (21).

263 There are several possible explanations for this finding in the literature, for instance,
264 discrete (binary) categorization of hypertension at the baseline as (yes or no) instead of
265 using blood pressure as a continuous variable (SBP, DBP). Binary categorization of
266 hypertension indeed did not reveal how severe it was at the baseline. This
267 categorization, due to insufficient information on blood pressure measurements, and
268 duration of antihypertensive medication use or any relevant treatment at the baseline
269 could have resulted in reporting normotensive or well-controlled hypertension patients
270 as hypertensive. Similar to our study, an Indonesian finding found a high blood pressure
271 that associated with a high risk of mortality though the risk is low compared to our
272 study (15).

273 Overall, this study can provide preliminary information about predictors that affect
274 survival status of CKD patients on hemodialysis in the three selected hemodialysis
275 centers in Addis Ababa, Ethiopia. Since we have limited information about this topic our
276 study would have paramount importance in recognizing the problems and complication
277 in hemodialysis patients. However, due to limited sample size of the study we might not

278 confidently rely on this information and we recommend further investigation by
279 overcoming the apparent limitation of this study. Being a retrospective study we were
280 unable to find some important predictors that should be considered in the study leaving
281 a question of potential residual confounding bias.

282 **Conclusions**

283 The survival status of hemodialysis patients in the three hospitals was low. Preventing
284 and treating comorbidities and complications during dialysis would reduce the
285 mortality of CKD patients.

286 **Funding**

287 Self-sponsored.

288 **Computing interest**

289 The authors declare that not have conflict of interest

290 **Ethics approval and consent to participate**

291 Ethical clearance was obtained from the Ethical Review Committee of Debre Berhan
292 University, College of Health Sciences (Protocol number: 12/21/CHS/SPH). Permission
293 was obtained from all Hospitals and dialysis Centers. Confidentiality and privacy of the
294 information were assured and maintained by preventing disclosure of the information
295 to third parties.

296 **Acknowledgements**

297 The authors give extended gratitude to Debre Berhan University College of Health
298 Sciences, Department of Public Health for providing the golden opportunity to carry out
299 this study, all staff members of SPHMMC, ZMH, MRH, Data collectors, family and friends
300 who supported in all efforts to accomplish the study.

301 **References**

302 [1. Jha V, Garcia-garcia G, Iseki K, Li Z, Naicker S, Plattner B, et al. Global Kidney

- 303 Disease 3 Chronic kidney disease : global dimension and perspectives. Lancet
304 [Internet]. 2013;382(9888):260–72. Available from:
305 [http://dx.doi.org/10.1016/S0140-6736\(13\)60687-X](http://dx.doi.org/10.1016/S0140-6736(13)60687-X)
- 306 2. Couser W, Remuzzi G, Mendis S, Tonelli M. The contribution of chronic kidney
307 disease to the global burden of major noncommunicable diseases. *Kidney Int.*
308 2011 Dec 1;80:1258–70.
- 309 3. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and
310 regional mortality from 235 causes of death for 20 age groups in 1990 and 2010:
311 A systematic analysis for the Global Burden of Disease Study 2010. *Lancet.*
312 2012;380(9859):2095–128.
- 313 4. Sumaili EK, Krzesinski JM, Zinga C V., Cohen EP, Delanaye P, Munyanga SM, et al.
314 Prevalence of chronic kidney disease in Kinshasa: Results of a pilot study from the
315 Democratic Republic of Congo. *Nephrol Dial Transplant.* 2009;24(1):117–22.
- 316 5. Shibiru T, Gudina EK, Habte B, Deribew A, Agonafer T. Survival patterns of
317 patients on maintenance hemodialysis for end stage renal disease in Ethiopia :
318 summary of 91 cases [Internet]. Vol. 14, *BMC Nephrology.* BMC Nephrology;
319 2013. 1 p. Available from: BMC Nephrology
- 320 6. Lakshmi KR, Nagesh Y, Veerakrishna M. Performance Comparison of Three Data
321 Mining Techniques for Predicting Kidney Dialysis Survivability. *Int J Adv Eng*
322 *Technol.* 2014;7(1):242–54.
- 323 7. Rezapour M, Zadeh MK, Sepehri MM. Implementation of Predictive Data Mining
324 Techniques for Identifying Risk Factors of Early AVF Failure in Hemodialysis
325 Patients. *Hindawi Publ Corp.* 2013;2013.
- 326 8. Rezapour M, Taran S, Parast MB. The impact of vascular diameter ratio on
327 hemodialysis maturation time : Evidence from data mining approaches and
328 thermodynamics. *MJIRI.* 2016;
- 329 9. Kore C, Tadesse A, Teshome B, Daniel K, Kassa A, Ayalew D. The Magnitude of
330 Chronic Kidney Disease and its Risk Factors at Zewditu Memorial Hospital, Addis
331 Ababa, Ethiopia. *J Nephrol Ther.* 2018;08(03):8–12.
- 332 10. Collins AJ, Foley RN, Chavers B, Gilbertson D, Herzog C, Johansen K, et al. US renal
333 data system 2011 Annual data report. *Am J Kidney Dis.* 2012;59(1 SUPPL. 1):A7.
- 334 11. Mekonen MW, Birahan KA, Chekole DM, Derso EA. Determinants of Overall
335 Survival of Kidney Failure for Patients Receiving Dialysis in Saint Geberial

- 336 General Hospital, Addis Ababa, Ethiopia. *J Kidney OPEN*. 2020;1–7.
- 337 12. Berhanu G, Tibebu, Jelaludin Ahmed , Abebaw Ferede S, Negera A, Bezu HTA,
338 Kassie K narayana. UG, Abelti G, et al. Population Projections for Ethiopia. In:
339 Central Statistical Agency. 2013.
- 340 13. Hussein M, Muleta G, Seyoum D, Kifle D, Bedada D. Survival Analysis of Patients
341 with End Stage Renal Disease the Case of Adama Hospital, Ethiopia Mekiya. *Clin*
342 *Med Res*. 2017;6(6):201–8.
- 343 14. Lima JJG De, Sesso R, Abensur H, Lopes HF, Giorgi MCP, Krieger EM, et al.
344 Nephrology Dialysis Transplantation Predictors of mortality in long-term
345 haemodialysis patients with a low prevalence of comorbid conditions. *Eur Dial*
346 *Transpl Assoc*. 1995;1708–13.
- 347 15. Urte Zakauskiene, Alvita Vickiene, Vaidas Vicka, Diana Sukackiene, Laurynas
348 Rimsevicius, Marius Miglinas. Institute of Clinical Medicine, Vilnius University
349 Faculty of Medicine V. E-POSTERS BLOOD PRESSURE DURING HEMODIALYSIS AS
350 PREDICTOR OF. *Wolters Kluwer Heal*. 2021;2021.
- 351 16. Tong J, Liu M, Li H, Luo Z, Huang J, Liu R, et al. Mortality and Associated Risk
352 Factors in Dialysis Patients with Cardiovascular Disease. *kidney international*.
353 2016;479–87.
- 354 17. Astor BC, Eustace JA, Powe NR, Klag MJ, Fink NE. Type of Vascular Access and
355 Survival among Incident Hemodialysis Patients : The Choices for Healthy
356 Outcomes in Caring for ESRD (CHOICE) Study. *Am Soc Nephrol*. 2005;1449–55.
- 357 18. Chang C, Fan P, Kuo G, Lin Y, Tsai T. Infection in Advanced Chronic Kidney Disease
358 and Subsequent Adverse Outcomes after Dialysis Initiation : A Nationwide Cohort
359 Study. *Sci Rep [Internet]*. 2020;1–10. Available from:
360 <http://dx.doi.org/10.1038/s41598-020-59794-7>
- 361 19. Salman Khazaei MY, Nematollahi1, ShahrzadZobdeh2, ZahraSheikh3,
362 VidaMMansournia ohammad A. Survival Rate and Predictors of Mortality among
363 Hemodialysis Patients in West of Iran , 1996 – 2015. *Int J Prev Med |*. 2018;1–5.
- 364 20. Clerck D, Bonkain F, Cools W, Niepen P Van Der. Vascular access type and
365 mortality in haemodialysis : a retrospective cohort study. *BMC Nephrol*. 2020;1–
366 7.
- 367 21. Georgianos PI, Agarwal R. Blood Pressure and Mortality in Long-Term
368 Hemodialysis — Time to Move Forward. *Am J Hypertens*. 2017;30(March):211–

369 22.

370

371


372

373


374

375 **Figure legends**


376



377



378



379

380

381 **Figure 1: Kaplan-Meier survival curves for hemodialysis patients, according to the mean of the covariate of**
382 **139 patients diagnosed in 2016-2020 in, Addis Ababa Ethiopia.**

383

384 **Tables**

385 **Table 1: Socio Demographic characteristics of 139 ESRD patients on maintenance**
 386 **hemodialysis for in Addis Ababa Ethiopia, from January 1st 2016 to December**
 387 **31st 2020**

Characteristic		Frequency(n)	Percentage
Age (mean ±SD (35.81±11.9))	18-34	77	55.4
	35-54	48	34.5
	≥55	14	10.1
Gender	Male	88	63.3
	Female	51	36.7
Occupation	Government	25	18.0
	Private	30	21.6
	Unemployed	57	41.0
	Farmer	1	0.7
	Student	6	4.3
	Not recorded	20	14.4
Residence	Addis Ababa	102	73.4
	Out of Addis Ababa	37	26.6
Marital status	Single	59	42.4
	Married	75	54.0
	Divorced	3	2.2
	Widow	2	1.4

388
 389
 390
 391
 392
 393
 394
 395
 396

397 **Table 2: Base line data blood pressure and weight with their statistical parameter**
 398 **ESRD patients on maintenance hemodialysis for in Addis Ababa Ethiopia, from**
 399 **January 1st 2016 to December 31st 2020**

Base line data of the patient	Mean	Median	Standard division	Range	Minimum	Maximum
Systolic BP(first)	143.95	140	21.935	129	92	221
Diastolic BP (first)	87	90	14.941	73	53	126
Systolic BP(last)	142.1	140	19	99	95	194
Diastolic BP(last)	84	86	13	86	44	130
Weight (first)	55.54	54	11.42	56.1	31.8	87.9
Weight(last)	54.9	53	10.99	57	30	87

400
 401
 402
 403
 404
 405
 406
 407
 408
 409
 410
 411
 412
 413
 414

415 **Table 3: Patient Laboratory value with their statistical parameter ESRD patients**
 416 **on maintenance hemodialysis for in Addis Ababa Ethiopia, from January 1st 2016**
 417 **to December 31st 2020**

Serum electrolyte (first and last)	Mean	Median	Standard deviation	Range	Minimum	Maximum
Creatinine(mg/dl)	8.9	8.6	3.55	18.0	2	20.04
Hemoglobin	10.37	10.1	2.27	11.1	5	16.1
Hematocrit	31.81	6.98	43	32	15.8	47.8
Phosphorus	2.21	1.7	1.59	7.47	0.43	7.9
Potassium	4.83	4.92	1.0	6.97	0.85	7.82
Calcium	3.39	2.23	2.4	8.7	0.92	9.61
Albumin	3.86	3.9	0.8	4.8	2.1	6.9
Sodium	136.7	138	6.59	48	99	147
Urea	104.2	96.8	46.1	202.6	10.4	213
Creatinine(mg/dl)	5.14	4.32	3.03	14.0	0.6	14.6
Hemoglobin	10.2	10.2	1.87	10	5	15
Hematocrit	31.35	31	6.12	32.5	15	47.5
Phosphorus	2.0	1.7	1.3	7.9	0.52	8.3
Potassium	4.95	4.9	0.99	4.8	2.9	7.7
Calcium	3.65	2.4	2.6	9.2	1.2	10.4
Albumin	3.5	3.5	0.54	3.0	2	5
Sodium	137.3	137.0	4.14	22	127	149
Urea	57	46	39	158.75	5.25	16.4

418 **Table 4: Treatment modalities for 139 ESRD patients on maintenance**
 419 **hemodialysis for in Addis Ababa Ethiopia, from January 1st 2016 to December**
 420 **31st 2020**

Variables	Characteristic	N (%)	Percentage
Frequency of dialysis session/week	Twice	15	10.8
	Three	124	89.2
Duration of dialysis per session	Three hours	5	3.6
	Three and half hours	13	9.4
	Four hours	121	87

Types of vascular access	Catheter	50	36
	Arteriovenous fistula	88	63.3
	Arteriovenous graft	1	0.7
Cause of CKD	Hypertension	67	48.2
	Diabetes mellitus	9	9
	Glomerulonephritis	9	9
	Renal stone	3	3
	Unknown	51	51
Blood transfusion	Yes	24	17.3
	No	115	82.7
EPO treatment	Yes	124	89.2
	No	15	10.8
Cause of death	Cardiovascular disease	6	25
	Infection	4/24	16.7
	Uremic complication	3/24	12.3
	Sudden death	4/24	16.7
	Hyperkalemia	1/24	4.1
	Cardiac arrest	2/24	8.3
	Cardiovascular disease	4/24	16.7

421

422

423 **Table 5: patient status for 139 ESRD patients on maintenance hemodialysis for in**
 424 **Addis Ababa Ethiopia, from January 1st 2016 to December 31st 2020**

Variable	Category	Total (%)	Number of event (%)	Censored (%)
Sex	Male	88(63.3)	15(17)	73(83)
	Female	51(36.7)	9(17.6)	42(82.4)
Resident	Addis Ababa	102(73.4)	19(18.63)	83(81.37)
	Out of Addis	37(26.6)	5(13.51)	32(86.49)

Marital status	Married	75(54.7)	12(16)	63(84)
	Unmarried	63(43.3)	12((19)	51(81)
Vascular access	AVF	88(63.3)	6(6.8)	82(93.2)
	Catheter	50(36)	17(34)	33(66)
	Graft	1(0.7)	1(100)	0(0)
Frequency of dialysis per week	Twice per week	15(10.8)	7(46.7)	8(53.3)
	Three per week	124(89.2)	17(13.7)	107(86.3)
Duration of dialysis	Three hours	5(3.6)	2(40)	3(60)
	Three and half hour	13(9.4)	4(30.8)	9(69.2)
	Four hours	121(87)	18((14.9)	10385.1)
Hypertension	Yes	96(69)	22(23)	74(77)
	No	43(31)	2(4.65)	41(95.35)
Diabetes mellitus	Yes	11(7.9)	3(27.3)	8(72.7)
	No	128(92.1)	21(16.4)	107(83.6)
albumin(mg/dl)	Under 3.5	57(41)	18(31.6)	39(68.4)
	3.51-4.00	45(32.4)	2(4.4)	43(95.6)
	Above 4.01	37(26.6)	4(10.8)	33(89.2)

425

426

427

428

429

430 **Table 6: unadjusted survival HR (95% CI) of ESRD patients on maintenance**
 431 **hemodialysis for in Addis Ababa Ethiopia, from January 1st 2016 to December**
 432 **31st 2020**

Variable	Category	p-value	Crude HR (95%CI)
Hypertension	Yes	0.047	4.331(1.018-18.431) *
	No*		1
Types of vascular access	Graft	0.036	10.069(1.166-86.976)
	Catheter	.000	9.479(3.558-25.24) ***
	Fistula*		1
Infection	Yes	0.038	3.625(1.071-12.255) *

	No*		1
Cardiovascular complication	Yes	0.015	4.495(1.338-15.105) *
	No*		1
Frequency of dialysis per week	Two times	0.28	2.7(1.116-6.533)
	Three times*		1
The reference categories were those indicated in asterisk (*)			

433 *Significant (P-value < 0.05), **significant (p-value<0.01) and*** significant (p<0.001)

434 CHR: - Crude Hazard Ratio, AHR: - Adjusted Hazard Ratio, HR=1 is reference variable.

435

436

437

438

439

440

441

442

443 **Table 7: adjusted survival HR (95% CI) of ESRD patients on maintenance**
 444 **hemodialysis for in Addis Ababa Ethiopia, from January 1st 2016 to December**
 445 **31st 2020**

Variable	Category	p-value	Unadjusted HR (95%CI)
Hypertension	Yes	0.015	7.139(1.474-34.565)
	No*		1
Types of vascular access	Graft	0.010	19.568(2.008-190.736)
	Catheter	0.09	3.839(1.404-10.498)
	Fistula*		1

Infection	Yes	0.035	3.586(1.985-13.054)
	No*		1
Cardiovascular complication	Yes	0.017	4.696(1.316-16.763)
	No*		1
The reference categories were those indicated in asterisk (*)			

446 NB: *Significant (P-value < 0.05), **significant (p-value<0.01) and*** significant
 447 (p<0.001) CHR: - Crude Hazard Ratio, AHR: - Adjusted Hazard Ratio, HR=1 is reference
 448 variable.